deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Confe...( REYKJAVIK Iceland Aug. 28 /- deCO...)

REYKJAVIK, Iceland, Aug. 28 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it will host a live webcast of deCODE CSO Jeffrey Gulcher's presentation at Thomas Weisel Partners Healthcare Conference 2008.

The presentation will be delivered at 1:30 PM ET / 5:30 PM GMT / 6:30 PM British Summer Time on Wednesday, September 3 at the Four Seasons Hotel, Boston, MA. The webcast can be accessed through the Investors page on deCODE's website, http://www.decode.com, and those interested in listening should log on a few minutes in advance in order to download any software or complete any sign-in that may be required. The webcast will be archived for at least one week.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com; on our diagnosti
'/>"/>